Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) presented additional entrainment and patient-level clinical data at SLEEP 2013, the 27th Annual Meeting of Associated Professional Sleep Societies in Baltimore, from its SET (Safety and Efficacy of Tasimelteon) and RESET (Randomized-withdrawal…
Source:Vanda reports clinical data of tasimelteon Phase III studies for treatment of Non-24-Hour Disorder
Wednesday, June 5, 2013
Vanda reports clinical data of tasimelteon Phase III studies for treatment of Non-24-Hour Disorder
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment